Becton, Dickinson and Company (BDX) Projected to Post Quarterly Earnings on Wednesday

Becton, Dickinson and Company (NYSE:BDX) will likely be posting its Q1 2026 results before the market opens on Wednesday, February 4th. Analysts expect Becton, Dickinson and Company to post earnings of $2.82 per share for the quarter. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, February 9, 2026 at 8:00 AM ET.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, beating the consensus estimate of $3.92 by $0.04. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The business had revenue of $5.89 billion for the quarter, compared to analysts’ expectations of $5.91 billion. During the same period in the prior year, the firm earned $3.81 earnings per share. Becton, Dickinson and Company’s revenue was up 8.3% compared to the same quarter last year. On average, analysts expect Becton, Dickinson and Company to post $14 EPS for the current fiscal year and $16 EPS for the next fiscal year.

Becton, Dickinson and Company Stock Performance

BDX stock opened at $203.41 on Wednesday. The company has a 50 day moving average price of $197.87 and a 200 day moving average price of $190.90. Becton, Dickinson and Company has a fifty-two week low of $162.29 and a fifty-two week high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64. The stock has a market capitalization of $57.95 billion, a PE ratio of 34.89, a price-to-earnings-growth ratio of 2.25 and a beta of 0.23.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 72.04%.

Becton, Dickinson and Company announced that its Board of Directors has authorized a stock buyback program on Tuesday, January 27th that permits the company to buyback $10.00 million in shares. This buyback authorization permits the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s management believes its stock is undervalued.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the sale, the executive vice president directly owned 12,095 shares in the company, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the transaction, the director owned 35,816 shares of the company’s stock, valued at $6,324,389.28. This trade represents a 0.60% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 2,605 shares of company stock worth $524,643. 0.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Becton, Dickinson and Company

Institutional investors have recently added to or reduced their stakes in the stock. Centaurus Financial Inc. lifted its holdings in shares of Becton, Dickinson and Company by 115.9% in the third quarter. Centaurus Financial Inc. now owns 3,767 shares of the medical instruments supplier’s stock valued at $705,000 after purchasing an additional 2,022 shares in the last quarter. Faithward Advisors LLC acquired a new stake in Becton, Dickinson and Company in the 3rd quarter valued at approximately $235,000. Coldstream Capital Management Inc. lifted its stake in Becton, Dickinson and Company by 10.8% in the 3rd quarter. Coldstream Capital Management Inc. now owns 5,400 shares of the medical instruments supplier’s stock valued at $1,011,000 after acquiring an additional 528 shares in the last quarter. Advisory Services Network LLC boosted its position in Becton, Dickinson and Company by 9.4% during the 3rd quarter. Advisory Services Network LLC now owns 19,086 shares of the medical instruments supplier’s stock worth $3,572,000 after acquiring an additional 1,637 shares during the last quarter. Finally, Hancock Whitney Corp grew its stake in shares of Becton, Dickinson and Company by 2.7% during the 3rd quarter. Hancock Whitney Corp now owns 11,953 shares of the medical instruments supplier’s stock worth $2,237,000 after acquiring an additional 310 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on BDX shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Piper Sandler cut their price target on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research note on Friday, November 7th. Stifel Nicolaus lifted their price objective on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Bank of America upped their price objective on Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a report on Monday, January 5th. Finally, Morgan Stanley boosted their target price on Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Four research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $207.64.

Becton, Dickinson and Company News Roundup

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Board declared a quarterly dividend of $1.05 per share (payable March 31; record date March 10), a direct shareholder return that supports income-focused investors. BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases
• Positive Sentiment: Company authorized an additional $10 million of share repurchases and has completed ~$250 million of repurchases in FY26 to date — buybacks and the dividend together signal management is focused on returning capital. BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases
• Positive Sentiment: Spin-off progress: BD set the Feb. 5 record date for the spin-off of its Biosciences & Diagnostic Solutions business and Waters shareholders approved the combination — a transaction that could unlock discrete value for BD shareholders and refocus BD on core med-tech operations. BD Announces Record Date for the Spin-Off Waters Shareholders Approve Combination
• Positive Sentiment: Product/technology: BD launched BD Research Cloud 7.0 with an AI-powered Horizon Panel Maker for advanced flow cytometry — a growth/competitive positive that supports longer-term revenue potential in life-science tools. BDX Introduces BD Research Cloud 7.0
• Neutral Sentiment: Upcoming results: BD scheduled its Q1 FY2026 earnings webcast — a near-term catalyst that could produce volatility depending on results and guidance. BD to Announce Financial Results for its First Quarter of Fiscal 2026
• Neutral Sentiment: Positive analyst/media pieces (Zacks, MSN) highlight BDX as an attractive value/momentum name — helpful for sentiment but not an immediate fundamental change. Why Becton Dickinson (BDX) is a top value stock for the long term Why Becton Dickinson (BDX) is a Top Value Stock
• Negative Sentiment: Scale concern: the newly authorized $10 million repurchase is small relative to BD’s ~$58B market cap, so some investors may view the buyback as immaterial to shares outstanding; expectations for larger capital returns may not be met. RTT News Buybacks

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.